Pfs25-Pfs230 malaria vaccine - MVI

Drug Profile

Pfs25-Pfs230 malaria vaccine - MVI

Alternative Names: PFS25 VLP & Pfs230 VLP; Pfs25-Pfs230 virus-like particle malaria vaccine - MVI; Pfs25/Alhydrogel and Pfs230D1M-EPA/Alhydrogel; Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01

Latest Information Update: 14 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Burnet Institute; Malaria Vaccine Initiative
  • Developer National Institute of Allergy and Infectious Diseases
  • Class Antimalarials; Parasitic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 01 Dec 2014 Phase-I clinical trials in Malaria prevention in USA (Parenteral)
  • 01 Dec 2014 Phase-I clinical trials in Malaria prevention in Mali (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top